Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis

EMBO Molecular Medicine

Volumn 5, Issue 1, 2013, Pages 105-121

  Saddoughi, Sahar A ^a,b   Gencer, Salih ^a,b   Peterson, Yuri K ^b   Ward, Katherine E ^c   Mukhopadhyay, Archana ^a,b   Oaks, Joshua ^d   Bielawski, Jacek ^a,b   Szulc, Zdzislaw M ^a,b   Thomas, Raquela J ^a,b   Selvam, Shanmugam P ^a,b   Senkal, Can E ^a,b   Garrett Mayer, Elizabeth ^b   De Palma, Ryan M ^a,b   Fedarovich, Dzmitry ^a,b   Liu, Angen ^b   Habib, Amyn A ^e,f   Stahelin, Robert V ^c,g   Perrotti, Danilo ^d   Ogretmen, Besim ^a,b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c UNIVERSITY OF NOTRE DAME   (United States)

^d OHIO STATE UNIVERSITY   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^f VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

^g INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Ceramide; FTY720; Sphingolipids; Sphingosine; Sphingosine kinase 2

Indexed keywords

CERAMIDE; FINGOLIMOD; NECROSTATIN; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN INHIBITOR; PROTEIN KINASE; PROTEIN RIPK1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CELL NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG TARGETING; ENZYME ACTIVATION; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MOLECULAR MODEL; MOUSE; NECROPTOSIS; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN DOMAIN; SIMULATION; SITE DIRECTED MUTAGENESIS; WILD TYPE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; GENE KNOCKDOWN TECHNIQUES; HISTONE CHAPERONES; HUMANS; LUNG NEOPLASMS; MICE; MICE, SCID; MODELS, MOLECULAR; NECROSIS; PHOSPHORYLATION; PROPYLENE GLYCOLS; PROTEIN PHOSPHATASE 2; RECEPTOR-INTERACTING PROTEIN SERINE-THREONINE KINASES; SPHINGOSINE; TRANSCRIPTION FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84871968824     PISSN: 17574676     EISSN: 17574684     Source Type: Journal    
DOI: 10.1002/emmm.201201283     Document Type: Article

References (45)

1. Berdyshev EV, Gorshkova I, Skobeleva A, Bittman R, Lu X, Dudek SM, Mirzapoiazova T, Garcia JG, Natarajan V (2009) FTY720 inhibits ceramide synthases and up-regulates dihydrosphingosine 1-phosphate formation in human lung endothelial cells. J Biol Chem 284: 5467- 5477
2. Bielawski J, Pierce JS, Snider J, Rembiesa B, Szulc ZM, Bielawska A (2010) Sphingolipid analysis by high performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS). Adv Exp Med Biol 688: 46- 59
3. Billich A, Bornancin F, Devay P, Mechtcheriakova D, Urtz N, Baumruker T (2003) Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases. J Biol Chem 278: 47408- 47415
4. Biton S, Ashkenazi A (2011) NEMO and RIP1 control cell fate in response to extensive DNA damage via TNF-alpha feedforward signaling. Cell 145: 92- 103
5. Bonapace L, Bornhauser BC, Schmitz M, Cario G, Ziegler U, Niggli FK, Schafer BW, Schrappe M, Stanulla M, Bourquin JP (2010) Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance. J Clin Invest 120: 1310- 1323
6. Chalfant CE, Kishikawa K, Mumby MC, Kamibayashi C, Bielawska A, Hannun YA (1999) Long chain ceramides activate protein phosphatase-1 and protein phosphatase-2A. Activation is stereospecific and regulated by phosphatidic acid. J Biol Chem 274: 20313- 20317
7. Cho YS, Challa S, Moquin D, Genga R, Ray TD, Guildford M, Chan FK (2009) Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation. Cell 137: 1112- 1123
8. Christofferson DE, Yuan J (2010) Necroptosis as an alternative form of programmed cell death. Curr Opin Cell Biol 22: 263- 268
9. Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, et al (2010) Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 362: 402- 415
10. Degterev A, Hitomi J, Germscheid M, Ch'en IL, Korkina O, Teng X, Abbott D, Cuny GD, Yuan C, Wagner G, et al (2008) Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat Chem Biol 4: 313- 321
11. Don AS, Martinez-Lamenca C, Webb WR, Proia RL, Roberts E, Rosen H (2007) Essential requirement for sphingosine kinase 2 in a sphingolipid apoptosis pathway activated by FTY720 analogues. J Biol Chem 282: 15833- 15842
12. Eichhorn PJ, Creyghton MP, Bernards R (2009) Protein phosphatase 2A regulatory subunits and cancer. Biochim Biophys Acta 1795: 1- 15
13. Hitomi J, Christofferson DE, Ng A, Yao J, Degterev A, Xavier RJ, Yuan J (2008) Identification of a molecular signaling network that regulates a cellular necrotic cell death pathway. Cell 135: 1311- 1323
14. Herzog F, Kahraman A, Boehringer D, Mak R, Bracher A, Waltzhoeni T, Leitner A, Beck M, Harti FU, Ban N, et al (2012) Structural probing of a protein phosphatase 2A network by chemical cross-linking and mass spectrometry. Science 337: 1348- 1352
15. Holler N, Zaru R, Micheau O, Thome M, Attinger A, Valitutti S, Bodmer JL, Schneider P, Seed B, Tschopp J (2000) Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nat Immunol 1: 489- 495
16. Karathanassis D, Stahelin RV, Bravo J, Perisic O, Pacold CM, Cho W, Williams RL (2002) Binding of the PX domain of p47(phox) to phosphatidylinositol 3, 4-biphosphate and phosphatidic acis is masked by an intramolecular interaction. EMBO J 21: 5057- 5068
17. Kudo N, Kumagai K, Tomishige N, Yamaji T, Wakatsuki S, Nishijima M, Hanada K, Kato R (2008) Structural basis for specific lipid recognition by CERT responsible for nonvesicular trafficking of ceramide. Proc Natl Acad Sci USA 105: 488- 493
18. Lahiri S, Park H, Laviad EL, Lu X, Bittman R, Futerman AH (2009) Ceramide synthesis is modulated by the sphingosine analog FTY720 via a mixture of uncompetitive and noncompetitive inhibition in an Acyl-CoA chain length-dependent manner. J Biol Chem 284: 16090- 16098
19. LaMontagne K, Littlewood-Evans A, Schnell C, O'Reilly T, Wyder L, Sanchez T, Probst B, Butler J, Wood A, Liau G (2006) Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization. Cancer Res 66: 221- 231
20. Li M, Makkinje A, Damuni Z (1996) The myeloid leukemia-associated protein SET is a potent inhibitor of protein phosphatase 2A. J Biol Chem 271: 11059- 11062
21. Liu Q, Alinari L, Chen CS, Yan F, Dalton JT, Lapalombella R, Zhang X, Mani R, Lin T, Byrd JC, et al (2010) FTY720 shows promising in vitro and in vivo preclinical activity by downmodulating Cyclin D1 and phospho-Akt in mantle cell lymphoma. Clin Cancer Res 16: 3182- 3192
22. Mukhopadhyay A, Saddoughi SA, Song P, Sultan I, Ponnusamy S, Senkal CE, Snook CF, Arnold HK, Sears RC, Hannun YA, et al (2009) Direct interaction between the inhibitor 2 and ceramide via sphingolipid-protein binding is involved in the regulation of protein phosphatase 2A activity and signaling. FASEB J 23: 751- 763
23. Muto S, Senda M, Akai Y, Sato L, Suzuki T, Nagai R, Senda T, Horikoshi M (2007) Relationship between the structure of SET/TAF-Ibeta/INHAT and its histone chaperone activity. Proc Natl Acad Sci USA 104: 4285- 4290
24. Neviani P, Santhanam R, Oaks JJ, Eiring AM, Notari M, Blaser BW, Liu S, Trotta R, Muthusamy N, Gambacorti-Passerini C, et al (2007) FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J Clin Invest 117: 2408- 2421
25. Ogretmen B, Hannun YA (2004) Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev Cancer 4: 604- 616
26. Paugh SW, Payne SG, Barbour SE, Milstien S, Spiegel S (2003) The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2. FEBS Lett 554: 189- 193
27. Pchejetski D, Paulmurugan R, Park S, Mickey BE, Asaithamby A, Saha D, Kelliher MA, Mukhopadhyay P, Banani F, Madden CJ, et al (2010) FTY720 (fingolimod) sensitizes prostate cancer cells to radiotherapy by inhibition of sphingosine kinase-1. Cancer Res 70: 8651- 8661
28. Pewzner-Jung Y, Ben-Dor S, Futerman AH (2006) When do Lasses (longevity assurance genes) become CerS (ceramide synthases)? insights into the regulation of ceramide synthesis. J Biol Chem 281: 25001- 25005
29. Pyne S, Bittman R, Pyne NJ (2011) Sphingosine kinase inhibitors and cancer: seeking the golden sword of Hercules. Cancer Res 71: 6576- 6582
30. Ramnarain DB, Paulmurugan R, Park S, Mickey BE, Asaithamby A, Saha D, Kelliher MA, Mukhopadhyay P, Banani F, Madden CJ, et al (2008) RIP1 links inflammatory and growth factor signaling pathways by regulating expression of the EGFR. Cell Death Differ 15: 344- 353
31. Roberts KG, Smith AM, McDougall F, Carpenter H, Horan M, Neviani P, Powell JA, Thomas D, Guthridge MA, Perrotti D, et al (2010) Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers. Cancer Res 70: 5438- 5447
32. Saddoughi SA, Garrett-Mayer E, Chaudhary U, O'Brien PE, Afrin LB, Day TA, Gillespie MB, Sharma AK, Wilhoit CS, Bostick R, et al (2011) Results of a phase II trial of gemcitabine plus doxorubicin in patients with recurrent head and neck cancers: serum C-ceramide as a novel biomarker for monitoring response. Clin Cancer Res 17: 6097- 6105
33. Salas A, Ponnusamy S, Senkal CE, Meyers-Needham M, Selvam SP, Saddoughi SA, Apohan E, Sentelle RD, Smith C, Gault CR, et al (2011) Sphingosine kinase-1 and sphingosine 1-phosphate receptor 2 mediate Bcr-Abl1 stability and drug resistance by modulation of protein phosphatase 2A. Blood 117: 5941- 5952
34. Senkal CE, Ponnusamy S, Manevich Y, Meyers-Needham M, Saddoughi SA, Mukhopadyay A, Dent P, Bielawski J, Ogretmen B (2011) Alteration of ceramide synthase 6/C16-ceramide induces activating transcription factor 6-mediated ER-stress and apoptosis via perturbation of cellular Ca+2 and ER/golgi membrane network. J Biol Chem 286: 42446- 42458
35. Seo SB, McNamara P, Heo S, Turner A, Lane WS, Chakravarti D (2001) Regulation of histone acetylation and transcription by INHAT, a human cellular complex containing the set oncoprotein. Cell 104: 119- 130
36. Stahelin RV, Cho W (2001) Differential roles of ionic, aliphatic, and aromatic residues in membrane-protein interactions: a surface plasmon resonance study on phospholipases A2. Biochemistry 40: 4672- 4678
37. Sun L, Wang H, Wang Z, He S, Chen S, Liao D, Wang L, Yan J, Liu W, Lei X, et al (2012) Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. Cell 148: 213- 227
38. Thon L, Mohlig H, Mathieu S, Lange A, Bulanova E, Winoto-Morbach S, Schutze S, Bulfone-Paus S, Adam D (2005) Ceramide mediates caspase-independent programmed cell death. FASEB J 19: 1945- 1956
39. Wallington-Beddoe CT, Hewson J, Bradstock KF, Bendall LJ (2011) FTY720 produces caspase-independent cell death of acute lymphoblastic leukemia cells. Autophagy 7: 707- 715
40. Wang Z, Jiang H, Chen S, Du F, Wang X (2012) The mitochondrial phosphatase PGAM5 functions at the convergence point of multiple necrotic death pathways. Cell 148: 228- 243
41. Weinlich R, Dillon CP, Green DR (2011) Ripped to death. Trends Cell Biol 21: 630- 637
42. Westermarck J, Hahn WC (2008) Multiple pathways regulated by the tumor suppressor PP2A in transformation. Trends Mol Med 14: 152- 160
43. Wooten-Blanks LG, Song P, Senkal CE, Ogretmen B (2007) Mechanisms of ceramide-mediated repression of the human telomerase reverse transcriptase promoter via deacetylation of Sp3 by histone deacetylase 1. FASEB J 21: 3386- 3397
44. Yeh E, Cunningham M, Arnold H, Chasse D, Monteith T, Ivaldi G, Hahn WC, Stukenberg PT, Shenolikar S, Uchida T, et al (2004) A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat Cell Biol 6: 308- 318
45. Zhang W, Yang J, Liu Y, Chen X, Yu T, Jia J, Liu C (2009) PR55 alpha, a regulatory subunit of PP2A, specifically regulates PP2A-mediated beta-catenin dephosphorylation. J Biol Chem 284: 22649- 22656